EVGN logo

Evogene (EVGN) News & Sentiment

Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
EVGN
seekingalpha.comMarch 6, 2025

Evogene Ltd. (NASDAQ:EVGN ) Q4 2024 Earnings Conference Call March 6, 2025 9:00 AM ET Company Participants Ofer Haviv - President and CEO Nir Nimrodi - Chairperson of the Board Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's Fourth Quarter Results Conference Call.

EverGen Infrastructure Provides Operations and Development Updates
EverGen Infrastructure Provides Operations and Development Updates
EverGen Infrastructure Provides Operations and Development Updates
EVGN
businesswire.comFebruary 28, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), announces operational updates at its Pacific Coast Renewables (“PCR”), and Prairie Sky Organics facilities. Pacific Coast Renewables Since acquiring the facility in 2021, EverGen has invested in a series of environmental performance improvements to meet the highest regulatory standards and prepare for the facility's expansion. As part of these efforts, EverGen has.

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
EVGN
prnewswire.comFebruary 13, 2025

Initial fungicidally active compounds already discovered REHOVOT, Israel , Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
EVGN
seekingalpha.comNovember 21, 2024

Evogene Ltd. (NASDAQ:EVGN ) Q3 2024 Earnings Conference Call November 21, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Amit Noam - CEO, Lavie BIO Operator Welcome to Evogene's Third Quarter Results Conference Call.

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
EVGN
prnewswire.comNovember 12, 2024

Lavie Bio intends to commence Yalos® sales for soybean in 2025 US spring season   REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
EVGN
prnewswire.comOctober 29, 2024

The shipment, comprising over 100 tons, was delivered to company's customer in Africa REHOVOT, Israel , Oct. 29, 2024 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company for oil production for bio-based products and biofuel, and a subsidiary of Evogene Ltd.

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
EVGN
prnewswire.comOctober 8, 2024

Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel , Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd.

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
EVGN
prnewswire.comAugust 23, 2024

REHOVOT, Israel , Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering.

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
EVGN
prnewswire.comAugust 12, 2024

REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
EVGN
prnewswire.comJuly 23, 2024

Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel , July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024.

  • 1(current)
  • 2
  • 1(current)
  • 2